

APPENDIX 5: DATA ABSTRACTION FORM — COST-EFFECTIVENESS

DATA ABSTRACTION FORM: Cost-Effectiveness (Q3)		
Reviewer		
RefID		
Author, date		
Study Characteristics		
Country setting	Canada	
Care setting		
Type of analysis		
Analysis perspective		
Description of study population (e.g., HCV high-risk group)		
Description of intervention		
Description of comparator		
Time horizon		
Model inputs		
Source of utilities		
Main assumptions		
Conflicts of interest (yes, no, none declared, not mentioned)		
Funding status		
Other		
Patient Characteristics		
	Intervention	Comparator
Number enrolled		
Number completing study		
Age (mean, SD or median, range)		
Female, n (%)		
Male, n (%)		
Other		
Outcomes		
	Intervention	Comparator
<ul style="list-style-type: none"> • ICER • ICUR • Cost-benefit ratio • Budget impact analysis outcomes 		
Comments		

HCV = hepatitis C virus; ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; n = number; SD = standard deviation.